THRD NASDAQ
Third Harmonic Bio, Inc.
1W: +0.0%
1M: -1.3%
3M: +4.3%
1Y: -50.5%
$5.38
Last traded 2025-08-12 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$242.8M
52W Range3.18-16.02
Volume1,416,403
Avg Volume262,783
Beta2.13
Dividend—
Analyst Ratings
Company Info
CEONatalie C. Holles
Employees31
SectorHealthcare
IndustryBiotechnology
IPO Date2022-09-14
Websitethirdharmonicbio.com
300 Technology Square
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617-915-6680
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Holles Natalie C. | J-Other | 998,854 | — | 2025-08-11 |
| Holles Natalie C. | J-Other | 50,000 | — | 2025-08-11 |
| Holles Natalie C. | J-Other | 1,218,836 | $5.35 | 2025-08-11 |
| Gladstone Michael | J-Other | 43,584 | — | 2025-08-11 |
| Murphy Christopher M | J-Other | 47,500 | — | 2025-08-11 |